Skip to main content

Aprea Therapeutics, Inc.

APRE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001781983

No open-market purchases or sales by Aprea Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $1.90M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 13, 2026
$5.91M
Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, +5 vs. previous quarter
27
13F valueReported value at the end of Q2 2026
$1.90M
Superinvestors holdingAt the end of Q2 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
–
No comparable prior period
Net income, FY2025
-$12.6M
No comparable prior period
Free cash flow, FY2025
–
No comparable prior period
Revenue, Q3 FY2026
–
No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
525.2K
Shares sold short
Change
−96.0K
−15.5% vs. previous
Days to cover
2.59
At average daily volume

Superinvestors holding APRE, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding APRE at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Aprea Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Apr 1, 2026 (view filing)Mar 311 dayHamill John P.SrVP/CFO/Prin Fin & Acct OfcrPPurchase+62.0K$0.81+$25.1K–31.0K afterDerivative2 lots
Apr 1, 2026 (view filing)Mar 311 dayPeters RichardDirectorPPurchase+247.8K$0.81+$100.4K–123.9K afterDerivative2 lots
Feb 2, 2026 (view filing)Jan 303 daysGilad OrenPresident/CEOPPurchase+28.1K$0.89+$25.0K+8.1%373.7K after
Feb 2, 2026 (view filing)Jan 303 daysGilad OrenPresident/CEOPPurchase+28.1K–––28.1K afterDerivative
Feb 2, 2026 (view filing)Jan 303 daysHamill John P.SrVP/CFO/Prin Fin & Acct OfcrPPurchase+5.70K$0.89+$5.07K+20.6%33.4K after
Feb 2, 2026 (view filing)Jan 303 daysHamill John P.SrVP/CFO/Prin Fin & Acct OfcrPPurchase+5.70K–––5.70K afterDerivative
Dec 11, 2025 (view filing)Dec 101 dayDuey MarcDirectorPPurchase+21.5K$1.17+$25.1K+9.1%256.2K after
Dec 11, 2025 (view filing)Dec 101 dayDuey MarcDirectorPPurchase+21.5K–––21.5K afterDerivative
Dec 11, 2025 (view filing)Dec 101 dayHamill John P.SrVP/CFO/Prin Fin & Acct OfcrPPurchase+5.00K$1.17+$5.85K+22.0%27.7K after
Dec 11, 2025 (view filing)Dec 101 dayHamill John P.SrVP/CFO/Prin Fin & Acct OfcrPPurchase+5.00K–––5.00K afterDerivative

Top 10 13F holders, Q2 2026

See all 27 holders

The largest institutional positions in Aprea Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding APRE in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
AIGH Capital Management LLC1,015,541$814.8K0.07%00.0%Unchanged
Vestal Point Capital, LP350,000$280.8K0.01%00.0%Unchanged
Sphera Funds Management Ltd.270,000$216.6K0.03%00.0%Unchanged
Nantahala Capital Management, LLC205,760$165.1K0.01%00.0%Unchanged
Renaissance Technologies LLC105,800$84.9K0.00%+80,700+321.5%Added
Geode Capital Management, LLC74,869$60.1K0.00%−44,262−37.2%Reduced
Citadel Advisors LLC58,600$47.0K0.00%+58,600New
BNP Paribas Arbitrage, SA45,211$36.3K0.00%+5,394+13.5%Added
Diadema Partners LP44,907$36.0K0.01%+44,907New
Vanguard Fiduciary Trust Co38,464$30.8K0.00%00.0%Unchanged

Holders of 5% or more of APRE

See all 4 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Aprea Therapeutics, Inc..

Largest holders of APRE from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Soleus Private Equity Fund III, L.P.13G9.99%1.27M sharesNewApr 1, 20261 filingApr 1, 2026SEC
Vestal Point Capital, LP13G9.90%22.7M sharesNewMay 15, 20261 filingMay 15, 2026SEC
Squadron Capital Management LLC13G9.90%1.27M sharesNewApr 7, 20261 filingApr 7, 2026SEC
Hirschman Orin13G/A9.90%1.19M shares0.00 ppfrom 9.90%Mar 3, 20235 filingsApr 27, 2026SEC